The aim of this study was to analyse the experience of Polish Pediatric Group for Hematopoietic Stem Cell Transplantation in respect to donor lymphocyte infusion procedure. The study included 51 pediatric patients with malignant (45) and non-malignant (6) diseases treated with DLI in the period 1993-2012. The indications for DLI were as follows: (1) increasing recipient chimerism after non-ablative hematopoietic SCT (18 patients); (2) immunomodulation after a reduced intensity conditioning regimen (2 patients); (3) increase in minimal residual disease detection (3 patients); and (4) relapse (28 patients). DLI was carried out at a median of 6 (0.5-79) months after SCT. DLI was administered as either a single-dose (in 19 cases) or in escalating-dose regimens (in 32 cases). The median total dose of CD3-positive T cells was 28.0 (0.1-730.0) × 10 6 /kg body weight. The time for assessment of DLI efficacy ranged from 0 to 70 (median 3) months. At evaluation, 18 patients experienced CR, 3 achieved PR, 19 showed relapse and 11 rejected the graft. DLI was found to be effective in 39% of cases. Complications of the procedure occurred in 18 patients; of these, 2 died. To sum up DLI shows efficacy in a significant percentage of children. Mortality related to the therapy adverse effects is low. However, this method requires standardization.
INTRODUCTION
Almost 30 years have passed since the clinical implementation of adoptive immunotherapy using donor lymphocyte infusion after allogeneic hematopoietic SCT (HSCT). 1 Nevertheless, the therapy still remains poorly recognized, mainly owing to numerous indications and the small number and huge diversity of patient groups treated with this method. [2] [3] [4] The main objective of DLI after HSCT is to improve the graft vs disease effect. 5, 6 Therefore, the treatment of malignancy relapse after HSCT is one of the most common applications of this method. 2, 7, 9 However, DLI found several other applications, particularly when CML ceased to be a standard indication for HSCT, and the number of non-myeloablative or reduced intensity conditioning (RIC) HSCT increased. In those types of HSCT, DLI is used to enhance engraftment or to prevent graft rejection when recipient chimerism is increasing, or to enhance the treatment effect in cases of persistent or increasing levels of residual disease detection. [7] [8] [9] However, when applying this therapy, it should be taken into account that its favorable effect is usually delayed for several months to even up to a year following administration. Moreover, DLI can induce aggravation of GVHD or BM aplasia. 4, 10, 11 The effective use of DLI has also been reported in cases of posttransplant lymphoproliferative disease and life-threatening viral infections that are resistant to standard therapy. [12] [13] [14] [15] The aim of our study was to assess the effectiveness and risk of toxicity of DLI in pediatric population. The study was retrospective and was based on the results of patient monitoring following HSCT treatment.
PATIENTS AND METHODS

Patient characteristics
The retrospective study evaluated 51 patients treated in five centers associated with Polish Pediatric Group for Hematopoietic Stem Cell Transplantation (PPGHSCT) centers, who received DLI between 1993 and 2012. The study group comprised 23 (45%) girls and 28 (55%) boys, at the median age of 9 (1-22) years, who received transplants for malignant (45 patients; ALL-13, AML-11, CML-7, myelodysplastic syndrome-7, solid tumor-3, non-Hodgkin lymphoma-2 and Hodgkin disease-2) and non-proliferative diseases (6 patients; chronic granulomatous disease-2, SCID-1, Fanconi anaemia-1, familial hemophagocytic lymphohistiocytosis-1 and mevalonic aciduria-1). In the malignancy group, before HSCT, 26 patients were in CR (I-12, II-12 and 4II-2), 5 in PR and 14 had progressive disease. The source of the graft was BM in 28 patients, mobilized peripheral blood in 19, cord blood in 2, peripheral blood and BM in 1 and cord blood and BM in 1 patient. Thirty-one patients had a HLA-matched sibling donor and 20 patients had an unrelated donor (HLA-matched-19 and HLA-mismatched-1). Immunosuppressive therapy (IT) was carried out in all patients; there were no data available on treatment duration in 11 cases, while in the remaining 40 patients it was carried out over an average period of 3 (1-11) months. After HSCT, acute GVHD was reported in 27 patients (assessed according to the Glucksberg classification as a stage I-II 0 in twenty and stage III-IV 0 in seven patients) 16 and chronic GVHD in six, including the mild form in two, moderate in one and severe in three patients (all assessed using the NIH global scoring system). 17 Indications for DLI were as follows: (1) increasing recipient chimerism after non-ablative (NA) HSCT (NA group; 18 patients, 35%); (2) immunomodulation after reduced intensity conditioning HSCT (RIC group; 2 patients, 4%); (3) enhancing the graft vs tumor effect in persistence or increase of minimal residual disease (MRD) after HSCT (MRD group, 3 patients, 6%); and (4) the post-transplant malignancy relapse (REL) treatment (REL group, 28 patients, 55%). In the NA group at the start of DLI, the mean donor/recipient chimerism was 71 ± 24%. In the REL group at the start of DLI, 23 had progressive disease, 4 were in the second PR and 1 patient had the third CR.
Data collection and statistical methods
The study was based on a questionnaire, and the results were drawn up on the basis of retrospective data obtained from the aforementioned centers by using tests in the Statistica 9.0 software package (StatSoft, Tulsa, OK, USA).
RESULTS
In the years 1993-2012, DLI was applied in 4.9% of all patients treated with HSCT in the PPGHSCT centers.
Time from HSCT to the start of DLI DLI was implemented at an average of 12 (0.5-79; median 6) months after HSCT. In 39 patients, the first DLI was performed within a year, and in 12 patients beyond a year after HSCT. The mean time for the DLI application in the NA group was 4 (0.5-12; median 5) months after HSCT. In the RIC group, the first DLI was used in the second and in the fourth month after HSCT. In the MRD group, the first DLI was performed at an average of 11 (4-21, median 9) months after HSCT, and in the REL group the first DLI was used at an average of 17 (2-79; median 8) months after HSCT. In the REL group, 18 patients underwent the DLI within a year and 10 patients beyond a year after HSCT. Statistical analysis showed significant differences in the time taken to perform DLI depending on the type of indication (P = 0.04).
Time from completion of IT to the start of DLI In the 40 patients, the mean time from completion of IT to the DLI was 141 (28 to 1758; median 49) days. In the remaining 11 patients, there were no data on the time of completion of IT. For the NA group, the mean time was 60 (28 to 242; median 42) days. In 1 patient, DLI was introduced 4 weeks before the completion of IT. For the RIC group, the first DLI was carried out 11 and 40 days after the completion of IT, and for the MRD group on days 33 and 539 (in one case there were no data). For the REL group, the mean time between the completion of IT and DLI was 233 (3-1758; median 78) days. The differences with respect to the interval between the completion of IT and application of the DLI were not significant (P = 0.18).
Time from diagnosis of indication for adoptive immunotherapy to the start of DLI The mean time from the appearance of the indication to the beginning of DLI in the whole group was 58 (0-474; median 20) days. For NA indication, it was 36 (0-320, median 5) days. For RIC, the time was 24 and 55 days, and for MRD the time was 1, 228 and 265 days. For the REL group, the mean time was 63 (0-475; median 30) days. Statistical analysis showed no significant differences (P = 0.12).
DLI and additional therapy applied according to indication In NA and RIC indication, DLI was applied exclusively. For MRD, DLI alone was used in two patients and DLI with tyrosine kinase inhibitor was used in one patient. For REL indication, the following therapy was applied: DLI alone in 15, DLI with targeted treatment (TT) in 2 (tyrosine kinase inhibitor in one and anti-CD33 in one) and DLI with different cytoreductive therapy (CT) in 11 patients.
When DLI was combined with TT, in REL indication, there was no information provided regarding time of this treatment introduction; in two other patients for MRD indication, the start of TT preceded DLI by 535 and 25 days, respectively.
When DLI was combined with CT, this therapy preceded DLI by an average of 78 (474-34; median 14) days in nine patients, and in one patient it was applied 34 days after the first DLI. In the remaining two patients, there was no information available regarding the day of CT application.
Source of donor lymphocytes The source of donor lymphocytes was as follows: non-stimulated and unselected peripheral blood cells collected by apheresis (21) , peripheral blood cells collected by apheresis after G-CSF mobilisation (29) and both methods (1 patient). The statistical analysis did not show any correlation between the source of lymphocytes and toxicity (P = 0.28), GVHD occurrence (P = 0.72) and outcome (P = 0.66) of DLI.
Number of infusions and dose of lymphocytes DLI was applied as a single-dose (19) When the source of DLI was G-CSF-mobilized blood stem cells, the CD34 content in the administered material was 4 (0.6-10; median 3) × 10 6 /kg BW on average.
Response to DLI The efficacy of DLI, depending on indication type, was assessed based on clinical symptoms and imaging studies (ultrasound, x-ray computed tompgraphy, magnetic resonance imaging), as well as by testing for donor chimerism and/or the monitoring of MRD according to individual practices of particular PPGHSCT centers. This was assessed at the time of the last contact or at the point of therapeutic decision. The mean time for assessment of DLI efficacy for the whole group was 12 (0.5-70; median 3) months.
At the final assessment, 18 patients (35%) experienced CR (NA-5, MRD-3 and REL-10), 2 (4%) experienced PR (RIC-1 and REL-1), 19 (37%) showed relapse or progression of disease (NA-5 and REL-14), 10 (20%) rejected the graft (NA-7, RIC-1 and REL-2) and 2 (4%) patients died because of DLI complications (NA-1 and REL-1).
The following were accepted as the expected results of DLI: disease progression delay, amelioration or CR, improvement of engraftment and increasing donor chimerism, and decrease in MRD. In the NA group, 5 (28%) patients achieved the results expected for DLI, in 12 (67%) patients this therapy was ineffective and 1 (5%) patient died because of side effects. In the RIC group, one patient achieved PR and another rejected the graft. In the MRD group, DLI therapy was effective in all patients, whereas in the REL group DLI was successful in 11 (39%), ineffective in 16 (57%) and 1 (5%) patient died because of DLI toxicity (Figure 1) .
Statistical analysis showed that the effectiveness of DLI in the whole study group correlated with the total dose of CD3-positive T cells (P = 0.02) and with the number of infusions administered (P = 0.03). There was no correlation (P40.05) between response to DLI and the type of indication, type of donor, sex of donor/ recipient, occurrence of GVHD after HSCT, source of lymphocytes, time-scheme DLI administration, time point of DLI implementation or using only DLI vs DLI in combination with another therapy.
Complications and DLI-related mortality The side effects of DLI were observed in 15 (30%) patients. In five patients, severe BM aplasia was reported, and GVHD appeared in 11 patients; moreover, in seven patients, GVHD was extensive.
Two (4%) patients died because of GVHD as a DLI complication; both had been treated because of a relapse of myelodysplastic syndrome, both were transplanted from unrelated donors and both had severe acute GVHD after HSCT. One of them had extensive chronic GVHD following DLI at a dose of 5 × 10 6 CD3-positive T cells/kg BW together with CD33 antibody. The second patient received DLI in escalating-dose regimens (the total dose was 221 × 10 6 CD3-positive T cells/kg BW). In the statistical analysis, DLI complications were significantly less common if the donor was a matched sibling (P = 0.02) and when DLI was not accompanied by any other form of additional treatment (P = 0.02). Other factors analyzed, such as the type of indication for DLI, type of disease, the occurrence of acute or chronic GVHD after HSCT, source of infused lymphocytes, sex of recipient/donor, time-scheme of application DLI, time between HSCT and DLI, and using only DLI vs DLI in combination with another therapy, had no impact on the reported complication rate (P40.05).
DISCUSSION
Treatment of malignancy relapse after HSCT is one of the most common applications of DLI, showing different efficacies depending on the type of disease and its clinical severity. The best results were reported in CML patients, followed by lymphoma, multiple myeloma and acute leukemia patients. The response to DLI was demonstrated as long-lasting only in CML patients. 18 In other diseases, the percentage of response to DLI was significantly lower, and the results obtained did not exceeded more than a delay in disease progression, decrease in intensity or delay of relapse. 2, [19] [20] [21] The data presented show that DLI therapy has been carried out relatively rarely (o 5% of HSCT) in PPGHSCT centers in the past. The most frequent indication for DLI was post-transplant disease relapse (54%), followed by increasing recipient chimerism after non-myeloablative transplantations (35%). Immunomodulation in RIC HSCT and increasing of MRD detection in this study were only limited indications (4 and 6%, respectively).
In our group of patients undergoing transplantation owing to malignant diseases treated with DLI, 16% were diagnosed with CML. A change in the therapeutic recommendations for CML patients made over the last decade, following the introduction of tyrosine kinase inhibitors, has resulted in a significantly decreased number of HSCT in this group of patients within the last few years. It has also had a significant impact on the decreased frequency of DLI in the treatment of CML relapse. 22, 23 The use of DLI as monotherapy to induce or strengthen the graft vs disease effect in the case of RIC HSCT in our patients did not show an explicit result of DLI in this condition. Indication for DLI combined with TT was the detection of increasing MRD levels (in one patient), and for DLI combined with TT or CT was the relapse of disease. Particular therapeutic protocols used in individual centers were quite different.
Application of DLI in response to increasing MRD markers pointed at the positive result of this treatment in our study. In the analyzed group DLI was administered to three patients (AML-2 and CML-1). CR was maintained in all of them with no significant complications of DLI. The number of patients was limited in the MRD group; nevertheless, observation of high effectiveness and low toxicity of DLI in patients with persistent residual disease is well confirmed. [24] [25] [26] The time of DLI infusion for NA and RIC indications was similar, and showed a small divergence in individual cases in comparison with the application time for MRD and REL indications. In the former case, this time was determined by the approximate course of HSCT and engraftment, whereas, in the latter, such a large dispersion was caused by the variability of disease nature after HSCT. Likewise, the time from occurrence of condition treated with DLI to administration of DLI was similar in NA and RIC indications (36 and 40 days, mean, respectively), and this time was used to prepare the donor and collect the lymphocytes. For REL indication, a mean time to administration of DLI was 63 days and was connected with TT or CT. Distinct differences can be seen in MRD indication in which the DLI was administered after a mean time of 165 (1-265) days of persistence of MRD. Such delay in DLI application shows that anticipated benefits of this therapy might have not been convincing enough in the concern of toxicity risk.
In our study, in the majority of cases, DLI was introduced after the completion of IT: for NA and RIC indications this was 2-6 weeks after completion, and for MRD and REL indications the time period was considerably longer and, as expected, conditioned by the variability of disease nature after HSCT.
The expected DLI effect was achieved in 39% of patients. A lack of DLI efficacy was shown in 57% patients. Huge divergence in the reported time at which DLI effectiveness was assessed (0-70 months) should, however, be emphasized. The only analyzed factors that had a significant impact on DLI effectiveness were the amount of CD3-positive T cells (P = 0.02) and the count of DLI doses (P = 0.03).
The majority of cases of poor response to DLI therapy in our cohort concerned the REL group. Levine et al. 27 reported a lack of advantage of DLI in children with hematologic malignancy relapse. Better results (26% of disease free survival) were obtained in relapses 46 months after HSCT in contrast to no response to therapy o 6 months from HSCT. 27 Authors pointed at better outcomes in children receiving DLI combined with CT. Those results are compatible with our findings of 39% of positive results of DLI in the REL group, where the majority of children presented later relapses.
DLI could benefit more successfully as pre-emptive therapy of malignancy recurrence after transplant, with the use of increasing recipient chimerism as a marker of relapse, than as a treatment of symptomatic relapse. In serial multicenter investigations, German authors proved, that in hematologic malignancies in children undergoing HSCT, promising results could be achieved with immunotherapy based on immunosupression cessation followed by DLI applied as pre-emptive therapy of impending relapse when compared with frank post transplant disease recurrence treatment. [28] [29] [30] Similar results were presented also by Rujkijyanont et al. 31 In our cohort, in over 1/3 of patients, DLI complications of different severity were observed. The most frequent was GVHD, a further was BM aplasia. Those complications were significantly more common in the group grafted from unrelated or unmatched donors (P = 0.02), and when DLI was applied in combination with TT or CT (P = 0.02). The DLI-related mortality rate for the whole group was 4%.
CONCLUSION
Our study shows that DLI could be the effective and safe form of therapy in children treated with HSCT. The application of DLI as pre-emptive therapy in cases of mixed chimerism or MRD markers detection should be developed; however, the method requires better understanding and further standardization.
